In today's competitive drug development market, biopharmaceutical businesses are always under pressure to provide high-quality medicines swiftly and affordably.
Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours.
China is a “big cancer country” with the population attacked by cancers ranking first in the world, which is a problem the Chinese patients and medical workers have to face.